Journal
HEART
Volume 108, Issue 8, Pages 626-632Publisher
BMJ PUBLISHING GROUP
DOI: 10.1136/heartjnl-2021-319503
Keywords
-
Categories
Funding
- Ib Mogens Kristiansens Almene Fond [30 206-383]
- Helsefonden [20-B-0035]
- Snedkermester Sophus Jacobsen og hustru Astrid Jacobsen Fond [J 167/1]
Ask authors/readers for more resources
This study investigated the risk of gastrointestinal bleeding associated with concomitant treatment of non-vitamin K oral anticoagulants and oral glucocorticoids. The results showed that the coexposure of these medications was linked to a higher short-term risk of gastrointestinal bleeding compared to patients solely on anticoagulants, suggesting the need for closer monitoring or risk mitigation strategies during combined treatment.
Objective Gastrointestinal bleeding (GIB) risk in relation to concomitant treatment with non-vitamin K oral anticoagulants (NOAC) and oral glucocorticoids is insufficiently explored. We aimed to investigate the short-term risk following coexposure. Methods This is a register-based, nationwide Danish study including patients with atrial fibrillation on NOACs during 2012-2018. Patients were defined as exposed to oral glucocorticoids if they claimed a prescription within 60 days prior to GIB. We investigated the associations between GIB and oral glucocorticoid exposure, reporting HRs via a nested case-control design and absolute risk via a cohort design. Matching terms were age, sex, calendar year, follow-up time and NOAC agent. Results 98 376 patients on NOACs (median age: 75 years (IQR: 68-82), 44% female) were included, and 16% redeemed at least one oral glucocorticoid prescription within 3 years. HRs of GIB were increased comparing exposed with non-exposed patients (<20 mg daily dose, HR 1.54 (95% CI 1.29 to 1.84); >= 20 mg daily dose, HR 2.19 (95% CI 1.81 to 2.65)). 60-day standardised absolute risk of GIB following first claimed oral glucocorticoid prescription increased compared with non-exposed: 60-day absolute risk: 0.71% (95% CI 0.58% to 0.85%) vs 0.38% (95% CI 0.32% to 0.43%). The relative risk was elevated as well: risk ratio of 1.89 (95% CI 1.43 to 2.36). Conclusions Concomitant treatment with NOACs and oral glucocorticoids was associated with a short-term rate and risk increase of GIB compared with patients only on NOACs. This could have implications for clinical management, necessitating closer monitoring or other risk mitigation strategies during episodes of cotreatment with oral glucocorticoids.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available